Mitigating Risk in the Supply Chain - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Mitigating Risk in the Supply Chain
The author describes the importance of risk management and offers strategies for risk-management preparedness in supply chains.

Pharmaceutical Technology
Volume 34, pp. s22-s28

Elements to assess supply disruption

A simple diagnostic test can assess whether a company is adequately prepared for supply-chain disruptions or mitigating reputational risk. Key questions to consider are:

  • Does a company have a comprehensive supply-chain risk-management program in place?
  • Does the supply-chain risk-management program have well-documented policies and procedures in place that adequately protect the company against the types of issues that are generating enormous news today (e.g., supply-chain disruptions such as geopolitical instability, natural disasters, financial collapse, inconsistent quality, contamination, and counterfeiting; corporate responsibility such as human rights violations and environmental concerns; and employee responsibility such as fraudulent activities, discrimination, and harassment)?
  • Are employees trained and certified in their understanding of these policies on an annual basis?
  • Is there a systematic process and data-management repository in place to ensure rapid and proactive response to unexpected events?
  • Are corporate responsibility and supply-chain risk-management a top priority among the company's senior executives?

The answers to these questions provide insight into whether a company is adequately prepared to mitigate risk in its supply-chain activities.

Gregg Brandyberry is a partner of Wildfire Commerce, senior advisor of AT Kearney procurement and analytic solutions, and former vice-president of procurement, global systems, and operations for GlaxoSmithKline, 629 Overhill Road, Ardmore, PA 19003, tel. 215.327.5739,


1. D. Gilmore, Supply Chain Digest, May 7, 2009.

2. FDA, Information on Heparin (Rockville, MD),, accessed June 30, 2010.

3. "The 2010 Global 100 List," Corporate Knights,, accessed July 15, 2010.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here